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Most of the innovative technologies used in percutaneous 
mitral interventions are based on well-standardised surgical 
procedures such as edge-to-edge repair or mitral annuloplasty. 
One of the first successful attempts to replicate surgical 
procedures in percutaneous interventions was represented by 
percutaneous balloon mitral valve commissurotomy (PMC). It 
dates back to 1984 when Inoue et al. [1] published the results 
of the first patients treated with transseptal mitral valvuloplasty 
for severe mitral stenosis (MS) in Japan. The Inoue balloon 
inserted from the femoral vein, usually sized according to the 
patient’s height, allowed a controlled dilatation of the valve to 
split the fused commissures and to obtain a significant increase 
of the mitral valve area (MVA).
Having started as an experimental treatment for inoper-
able patients, PMC rapidly evolved into a well-established 
procedure by becoming the gold-standard therapy for 
symptomatic MS with favourable characteristics, as reported 
by the latest 2017 European Society of Cardiology/European 
Association for Cardio-Thoracic Surgery (ESC/EACTS) guide-
lines [2]. The European task force highlighted the importance of 
percutaneous valvuloplasty not only for symptomatic patients 
(class of recommendation I) but also for asymptomatic ones 
without unfavourable characteristics and at high risk of throm-
boembolism or haemodynamic decompensation (class IIa). 
Mitral valve surgery, despite the proven long-term results [3], 
remains indicated only for patients with severe MS not suit-
able for PMC, or as a second-line therapy. 
Over the last two decades in Western countries, the preva-
lence of MS has progressively shifted from rheumatic disease of 
young patients to degenerative stenosis typical of the elderly, 
increasing the importance of the non-surgical approach.
Optimal candidate selection for PMC remains the most 
crucial factor to obtain excellent outcomes [4]. Over the years, 
many scores which focused on echocardiographic charac-
teristics of the stenotic valve have been proposed to identify 
predictors for immediate and long-term results [5–7]. The 
importance of preoperative echocardiographic assessment 
is recognised by all experienced surgeons and interventional 
cardiologists; accurate evaluation of not only the dysfunctional 
valve, but also the subvalvular apparatus and commissural 
calcifications, impacts the outcomes of both surgical and 
percutaneous procedures. 
The absence of commissural fusion or the presence of 
severe or bi-commissural calcifications are usually considered 
major contraindications for PMC, as well as the evidence of 
left atrial thrombosis, more than mild mitral regurgitation, or 
concomitant diseases requiring surgery. 
Centres which are experienced in mitral valve disease 
treatment, with a high volume of surgical and percutaneous 
mitral repair, can achieve good results also in non-optimal 
candidates, as demonstrated by Dreyfus et al. [8] in a series of 
464 patients with unfavourable commissural anatomy. These 
excellent results, compared to others previously reported 
for patients unfavourable to PMC [9], can be obtained only 
with a scrupulous patient selection, an excellent technical 
performance, and a perfectly integrated cardiac imaging 
acquisition during the preoperative and the intraoperative 
phases. The use of three-dimensional echocardiography and 
computed tomo graphy imaging for preoperative screening 
plays a fundamental role in optimising patient selection, and 
allows extremely accurate evaluation of valve pathology [10]. 
The MVA is frequently used as the first cut-off in MS 
management due to the strict correlation between MVA and 
clinical presentation. 
In standard practice, a value of MVA lower than 1.5 cm2 is 
routinely used by operators as a cut-off for PMC indication. 
Nevertheless, many authors reported good results of val-
vuloplasty also for moderate or even mild mitral stenosis 
(MVA > 1.5 cm2) with increased pulmonary pressure or 
other signs of initial decompensation [11, 12]. In fact, it is 
common to observe MS-related symptoms even in patients 
with a MVA greater than 1.5 cm2. Dealing with this class of 
patients, especially when they are young and have a long 
life expectancy, is always challenging. In many cases, also 
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with suboptimal anatomy, PMC could be a good option to 
delay surgery or at least to diminish symptoms, but only if 
the decision-making process is held in a high-volume centre 
with excellent expertise in the mitral valve disease treat-
ment. Young patients with severe MS can benefit from this 
approach permitting postponement of mitral valve replace-
ment, avoiding a longer anticoagulation regimen in the case 
of mechanical prosthesis implantation or early deterioration 
in the case of bioprosthesis.
Tyczyński et al. [13] retrospectively analysed 1794 con-
secutive patients treated with PMC for symptomatic MS 
at the Institute of Cardiology in Warsaw since 1988. The 
results of this study confirmed the efficacy and the safety of 
the procedure. Moreover, they demonstrated that even the 
subgroup of patients with preoperative MVA > 1.5 cm2 expe-
rienced a significant reduction of the left atrial pressure and 
an increase of the valve area — two of the most important 
predictors of good long-term outcomes [14]. As underlined 
by the authors, going beyond classical indications requires 
not only demonstration of feasibility but also remarking on 
the potential periprocedural risks, mainly represented by 
the possibility of significant post-procedural increase of mi-
tral regurgitation. The failure rate did not significantly differ 
between the two groups and remained comparable to the 
values published in literature, permitting new perspectives for 
PMC indications in the future, if larger randomised studies 
with longer follow-up confirm these results. 
The expansion of PMC indications in the near future 
should deal with the promising perspectives of new tran-
scatheter mitral valve implantations (TMVI), especially in 
severe mitral annulus calcification [15]. The available data are 
still limited and TMVI is often used as a last option for very 
high-risk patients, bringing 30-day mortality in mitral annulus 
calcification up to 20%. However, the arrival of new devices 
in the clinical arena and the increased skill of the operators 
will probably revolutionise the scenario. 
Taking into consideration the worldwide clinical needs, 
especially in developing countries, the need for a cheap, 
easily reproducible, percutaneous treatment for MS seems 
clear. In this scenario, PMC could remain a good option 
also in the future. The technique is still mainly based on the 
30-year-old Inoue balloon, giving a chance for technological 
improvements in the near future.
However, the management of early or late failure of PMC 
linked to post-procedural mitral insufficiency or progressive 
restenosis remains an open issue. 
In the next few years, high-volume valve centres should 
improve their multidisciplinary team organisation, trying to 
offer a real patient-oriented approach in order to propose 
the best solution for mitral disease based not only on valve 
anatomy but also on the patient’s characteristics, life expec-
tancy, and future technologies. 
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